๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Selegiline delays the onset of disability in de novo parkinsonian patients

โœ Scribed by Palhagen, S.; Heinonen, E. H.; Hagglund, J.; Kaugesaar, T.; Kontants, H.; Maki-Ikola, O.; Palm, R.; Turunen, J.

Book ID
115523708
Publisher
Lippincott Williams and Wilkins
Year
1998
Tongue
English
Weight
768 KB
Volume
51
Category
Article
ISSN
0028-3878

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Selegiline in de novo parkinsonian patie
Selegiline in de novo parkinsonian patients: The finnish study
โœ Prof. V. V. Myllylรค; K. A. Sotaniemi; J. A. Vuorinen; E. H. Heinonen ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 353 KB

Selegiline (L-deprenyl) has been recommended as an antiparkinsonian drug to be used as an adjunct to therapy with L-dopa, if and when L-dopa starts to lose its effect. However, initial selegiline monotherapy followed by L-dopa may be both effective and safe. A double-blind, placebo-controlled trial